Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.

Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, Axelrod JD, Cheyette BN, Simon MI, Lester HA, Schwarz J.

J Neurosci. 2005 Feb 23;25(8):2157-65.

2.

RGS9-2 mediates specific inhibition of agonist-induced internalization of D2-dopamine receptors.

Celver J, Sharma M, Kovoor A.

J Neurochem. 2010 Aug;114(3):739-49. doi: 10.1111/j.1471-4159.2010.06805.x. Epub 2010 May 8.

3.

The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.

Yin LL, Geng XC, Zhu XZ.

Brain Res Bull. 2011 Nov 25;86(5-6):367-72. doi: 10.1016/j.brainresbull.2011.09.016. Epub 2011 Sep 24.

PMID:
21963945
4.

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A, Qin C, LaHoste GJ, Li Q, Bioulac BH, Waugh JL, Gurevich E, Neve RL, Bezard E.

J Neurosci. 2007 Dec 26;27(52):14338-48.

5.

RGS9 modulates dopamine signaling in the basal ganglia.

Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A, Chen CK, DiLeone RJ, Schwarz SC, Selley DE, Sim-Selley LJ, Barrot M, Luedtke RR, Self D, Neve RL, Lester HA, Simon MI, Nestler EJ.

Neuron. 2003 Jun 19;38(6):941-52.

6.

D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.

Ballion B, Frenois F, Zold CL, Chetrit J, Murer MG, Gonon F.

Neurobiol Dis. 2009 Sep;35(3):376-84. doi: 10.1016/j.nbd.2009.05.019. Epub 2009 Jun 6.

PMID:
19501163
7.

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.

Biol Psychiatry. 2009 Sep 15;66(6):603-13. doi: 10.1016/j.biopsych.2009.04.025. Epub 2009 Jun 11.

PMID:
19520364
8.

Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.

Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M.

Synapse. 2008 Jul;62(7):524-33. doi: 10.1002/syn.20527. Erratum in: Synapse. 2008 Dec;62(12):958. Lucia, Frau [corrected to Frau, Lucia]; Annalisa, Pinna [corrected to Pinna, Annalisa]; Silvia, Pontis [corrected to Pontis, Silvia]; Nicola, Simola [corrected to Simola, Nicola]; Nicoletta, Schintu [corrected to Schintu, Nicoletta]; Micaela, Morelli [corrected to Morelli, Micaela].

PMID:
18435422
9.
11.

Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements.

Naidu PS, Kulkarni SK.

Methods Find Exp Clin Pharmacol. 2000 Dec;22(10):747-51.

PMID:
11346896
12.

The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.

Kuzhikandathil EV, Bartoszyk GD.

Neuropharmacology. 2006 Sep;51(4):873-84. Epub 2006 Jul 14.

PMID:
16844149
13.

Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex.

Maple AM, Perna MK, Parlaman JP, Stanwood GD, Brown RW.

Eur J Neurosci. 2007 Nov;26(9):2532-8. Epub 2007 Oct 23.

PMID:
17970732
14.

Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia.

Liou YJ, Chen ML, Wang YC, Chen JY, Liao DL, Bai YM, Lin CC, Chen TT, Mo GH, Lai IC.

Am J Med Genet B Neuropsychiatr Genet. 2009 Mar 5;150B(2):239-42. doi: 10.1002/ajmg.b.30796.

PMID:
18548510
15.

Endogenous dopaminergic tone and dopamine agonist action.

Treseder SA, Smith LA, Jenner P.

Mov Disord. 2000 Sep;15(5):804-12.

PMID:
11009183
17.

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9. Review.

PMID:
15885624
18.

Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.

Van Kampen JM, Stoessl AJ.

Neuroscience. 2000;101(3):629-35.

PMID:
11113312
20.

Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity.

Marin C, Tolosa E.

Neuropharmacology. 1997 Aug;36(8):1115-7.

PMID:
9294977

Supplemental Content

Support Center